Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H30F2N2O4 |
| Molecular Weight | 460.5135 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@@H](CNCCCCCCOCC(F)(F)C1=CC=CC=C1)C2=CC=C(O)C3=C2C=CC(=O)N3
InChI
InChIKey=SFYAXIFVXBKRPK-QFIPXVFZSA-N
InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1
Abediterol, a fast and long-acting β2-adrenoceptor agonist (LABA), is being developed by AstraZeneca, for the treatment of asthma and chronic obstructive pulmonary disease. The investigational drug is a long-acting beta2-agonist (LABA) that has a bronchodilator effect, relaxing the muscles around the airways. It is currently under development and is in Phase II clinical trials.
Originator
Approval Year
Sample Use Guides
The first Phase 2 study of abediterol as a COPD treatment was completed in 2012. It evaluate four single doses of inhaled abediterol at 0.625, 2.5, 5 or 10 ug. Results showed that all doses significantly improved bronchodilation when compared to a placebo. Doses of 2.5, 5, and 10 ug also showed improvements when compared to the active comparator.
Route of Administration:
Respiratory
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 19:16:59 GMT 2023 , Edited by admin on Fri Dec 15 19:16:59 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
ABEDITEROL
Created by
admin on Fri Dec 15 19:16:59 GMT 2023 , Edited by admin on Fri Dec 15 19:16:59 GMT 2023
|
PRIMARY | |||
|
DTXSID60238605
Created by
admin on Fri Dec 15 19:16:59 GMT 2023 , Edited by admin on Fri Dec 15 19:16:59 GMT 2023
|
PRIMARY | |||
|
QXA167CM6F
Created by
admin on Fri Dec 15 19:16:59 GMT 2023 , Edited by admin on Fri Dec 15 19:16:59 GMT 2023
|
PRIMARY | |||
|
142077
Created by
admin on Fri Dec 15 19:16:59 GMT 2023 , Edited by admin on Fri Dec 15 19:16:59 GMT 2023
|
PRIMARY | |||
|
915133-65-2
Created by
admin on Fri Dec 15 19:16:59 GMT 2023 , Edited by admin on Fri Dec 15 19:16:59 GMT 2023
|
PRIMARY | |||
|
11962616
Created by
admin on Fri Dec 15 19:16:59 GMT 2023 , Edited by admin on Fri Dec 15 19:16:59 GMT 2023
|
PRIMARY | |||
|
DB12100
Created by
admin on Fri Dec 15 19:16:59 GMT 2023 , Edited by admin on Fri Dec 15 19:16:59 GMT 2023
|
PRIMARY | |||
|
C132738
Created by
admin on Fri Dec 15 19:16:59 GMT 2023 , Edited by admin on Fri Dec 15 19:16:59 GMT 2023
|
PRIMARY | |||
|
ZZ-25
Created by
admin on Fri Dec 15 19:16:59 GMT 2023 , Edited by admin on Fri Dec 15 19:16:59 GMT 2023
|
PRIMARY | |||
|
300000024924
Created by
admin on Fri Dec 15 19:16:59 GMT 2023 , Edited by admin on Fri Dec 15 19:16:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL3039530
Created by
admin on Fri Dec 15 19:16:59 GMT 2023 , Edited by admin on Fri Dec 15 19:16:59 GMT 2023
|
PRIMARY | |||
|
9406
Created by
admin on Fri Dec 15 19:16:59 GMT 2023 , Edited by admin on Fri Dec 15 19:16:59 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
